BioSpace News Archive

Business

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization Board of Directors for the 2021-2022 term.

June 14, 2021
·
2 min read
Policy

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure

Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced that the FDA has accepted a Pre-IND request for a potential functional cure or treatment of HIV.

June 14, 2021
·
4 min read
Drug Development

Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer’s Disease

Anavex Life Sciences Corp. reported that ANAVEX®2-73 and ANAVEX®3-71 are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets, titled “The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer’s”.

June 14, 2021
·
12 min read
Drug Development

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients

Landos Biopharma, Inc. announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for omilancor, its lead candidate in late-stage clinical development for the treatment of mild-to-moderate active ulcerative colitis patients.

June 14, 2021
·
6 min read
iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

iTeos Therapeutics and GlaxoSmithKline plc announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer.

June 14, 2021
·
11 min read
Genetown

Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference

Leap Therapeutics, Inc. today announced that Douglas E. Onsi , President and Chief Executive Officer, will present a corporate overview at the Raymond James 2021 Virtual Human Health Innovation Conference on Monday, June 21, 2021.

June 14, 2021
·
3 min read
Business

Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer

Forma Therapeutics Holdings, Inc. today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer.

June 14, 2021
·
4 min read
Policy

Number of Shares and Voting Rights of Innate Pharma as of June 1, 2021

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as of June 1, 2021

June 14, 2021
·
4 min read
Drug Development

TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.

June 14, 2021
·
4 min read
Chinese biotech firm Vazyme to showcase full range of COVID-19 Testing Solutions at Medlab

Chinese biotechnology company Vazyme will showcase a rich lineup of products at the 2021 Medlab Middle East, a leading medical laboratory exhibition co-located with Arab Health.

June 14, 2021
·
4 min read